Oppenheimer upgraded Dyne Therapeutics (DYN) on Wednesday, citing a positive read-through from data that Novartis’ (NVS) buyout target Avidity Biosciences (RNA) is set to release this year from a late ...
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the stocks that will double in 2026. On December 9, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio, with a price target of $15.
Investing.com-- Oppenheimer slashed its price target on Q32 Bio Inc (NASDAQ:QTTB) after the firm released mixed results from two ongoing phase 2 trials for its Bempikibart treatment. Oppenheimer ...
On Tuesday, Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an Outperform rating. This heightened optimism is driven by positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results